Returns on research and development for 1990s new drug introductions

PharmacoEconomics

Volumn 20, Issue SUPPL. 3, 2002, Pages 11-29

  Grabowski, Henry ^a   Vernon, John ^a   DiMasi, Joseph A ^b  

^a DUKE UNIVERSITY   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEW DRUG;

CONFERENCE PAPER; COST; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; MANAGED CARE ORGANIZATION; PRIORITY JOURNAL; UNITED STATES;

EID: 0036441845     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200220003-00002     Document Type: Conference Paper

References (28)

1. Grabowski H, Vernon J. Returns to R&D on new drug introductions in the 1980s. J Health Econ 1994; 13: 383-406
2. Grabowski H, Vernon J. A new look at the returns and risks to pharmaceutical R&D. Manage Sci 1990; 36 (7): 167-85
3. Scherer FM. The link between gross profitability and pharmaceutical R&D spending. Health Aff 2001; 20 (5): 136-40
4. Shulman S, Healy EM, Lasagna L, editors. PBMs: Reshaping the Pharmaceutical Distribution Network. New York: Haworth Press, 1998
5. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: New estimates of drug development costs. J Health Econ 2002. In Press
6. Congress of the United States. Congressional Budget Office. How Health Care Reform Affects Pharmaceutical Research and Development. Washington: US Government Printing Office, Jun 1994
7. Congress of the United States. Congressional Budget Office. How Increased Competition from Generic Drugs has Affected Prices and Returns in the Pharmaceutical Industry. Washington: US Government Printing Office, Jul 1998
8. Grabowski H, Vernon J. The distribution of sales revenues from pharmaceutical innovation. Pharmacoeconomics 2000; 18 Suppl. 1: 21-32
9. Myers SC, Shyum-Sunder L. Measuring pharmaceutical industry risk and the cost-of-capital. In: Helms RB, editor. Competitive Strategies in the Pharmaceutical Industry. Washington (DC): AEI Press, 1996: 208-37
10. US Congress, Office of Technology Assessment Pharmaceutical R&D. Costs, Risks and Rewards. Washington (DC): US Government Printing Office, 1993
11. Myers SC, Howe CD. A Life-Cycle Financial Model of Pharmaceutical R&D: Working Paper; Program on the Pharmaceutical Industry. Cambridge (MA): MIT, 1997
12. Poterba JM, Summers LH. A CEO survey of US companies time horizons and hurdle rates. Sloan Manage Rev 1995; Fall: 43-53
13. DiMasi J, Hansen R, Grabowski H, et al. The cost of innovation in the pharmaceutical industry. J Health Econ 1991; 10: 107-42
14. Thomas LG. Industrial policy and international competitiveness in the pharmaceutical industry. In: Helms B, editor. Competitive Strategies in the Pharmaceutical Industry. Washington (DC): AEI Press, 1996: 107-129
15. Annual report: The Med Ad News 500: The world's best-selling medicines. Med Ad News 2001; 20 (5)
16. Grabowski H, Vernon J. Effective patent life in pharmaceuticals. Int J Technol Manag 2000; 19: 98-120
17. Burstall ML, Reuben BG, Reuben AJ. Pricing and reimbursement regulation in Europe: An update of the industry perspective. Drug Inf J 1999; 33: 669-88
18. Rosenthal MB, Berndt ER, Donohue JM, et al. Promotion of prescription drugs to consumers. N Engl J Med 2002; 346 (7): 498-505
19. Best Practices LLC. Global marketing launch: An executive summary. Chapel Hill, NC (USA): Best Practices, Feb 2000. Available on the web with associated reports from: URL: http://internet8.eapps.com/bestp/domrep
20. Scherer FM, Harkoff D, Kudies J. Uncertainty and the size distribution of rewards from technological innovation. J Evolut Econ 2000; 10: 175-200
21. Grabowski H, Vernon J. The determinants of pharmaceutical research and development expenditures J. Evolut Econ 2000; 10: 201-15
22. Cutler DM, McClellan M. Is technological change in medicine worth it? Health Aff 2000; 20 (5): 11-29
23. Lichtenberg FR. Are the benefits of newer drugs worth their cost?.: Evidence from the 1996 MEPS. Health Aff 2000; 20 (5): 241-51
24. Grabowski H. Drug Regulation and Innovation. Washington: AEI Press, 1976
25. Baily MN. Research and development costs and returns: The US pharmaceutical industry. J Pol Econ 1972; 80 (1): 70-85
26. Scherer FM. Technological maturity and waning economic growth. Arts and Sciences 1978; 1: 7-11
27. Anderson WH, Fitzgerald CQ, Manasco PK. Current and future applications of pharmacogenomics. New Horiz 1999; 7 (2): 262-29
28. The Fruits of Genomics: Drug Pipelines Face Indigestion until the New Biology Ripens. New York: Lehman Brothers, Jan 2001